PapersFlow Research Brief
Biomedical Research and Pathophysiology
Research Guide
What is Biomedical Research and Pathophysiology?
Biomedical Research and Pathophysiology is a field studying nephropathic cystinosis, a rare genetic lysosomal storage disorder caused by CTNS gene mutations, focusing on its pathogenesis, cysteamine therapy, renal and ocular complications, and disruptions in autophagy and mitochondrial function.
This field centers on nephropathic cystinosis, encompassing molecular genetics of CTNS gene mutations, lysosomal dysfunction, and organ-specific complications like renal failure and corneal cystine crystals. Research includes over 25,200 works on cysteamine therapy's role in depleting cystine accumulation and impacts on cellular processes such as the pentose phosphate pathway and transaldolase deficiency. Growth data over the past five years is not available.
Topic Hierarchy
Research Sub-Topics
CTNS Gene Mutations in Nephropathic Cystinosis
This sub-topic analyzes over 100 CTNS mutations causing cystinosis, their genotype-phenotype correlations, and functional impacts on cystine transport. Researchers use sequencing, CRISPR models, and patient registries to study disease severity variations.
Cysteamine Therapy in Cystinosis Management
Research evaluates cysteamine's efficacy in cystine depletion, optimal dosing, adherence challenges, and long-term outcomes in renal preservation and growth. Clinical trials assess delayed-release formulations and combination therapies.
Renal Complications of Nephropathic Cystinosis
This area covers Fanconi syndrome, glomerular hyperfiltration, tubulopathy progression to end-stage renal disease, and biomarkers like NGAL for early detection. Studies explore renal histology and transplantation outcomes in cystinosis patients.
Ocular Manifestations in Cystinosis
Researchers investigate corneal cystine crystals, photophobia, retinopathy, and topical cysteamine efficacy using slit-lamp biomicroscopy and OCT imaging. Long-term visual outcomes and novel ocular delivery systems are key focuses.
Autophagy Impairment in Lysosomal Storage Disorders
This sub-topic examines cystine accumulation's disruption of autophagy-lysosomal flux, mTOR regulation, and therapeutic restoration using TFEB activators in cystinosis models. It links to broader lysosomal diseases like Fabry and Gaucher.
Why It Matters
Research in this field addresses nephropathic cystinosis, which causes progressive renal failure and multi-organ damage due to lysosomal cystine buildup from CTNS mutations. Cysteamine therapy targets cystine depletion to mitigate renal and ocular complications, as explored in studies on lysosomal storage disorders. For instance, Meikle et al. (1999) in "Prevalence of Lysosomal Storage Disorders" noted that while individually rare, these disorders collectively represent a significant health issue in populations like Australia, informing screening and treatment strategies. Eng et al. (2001) in "Safety and Efficacy of Recombinant Human α-Galactosidase A Replacement Therapy in Fabry's Disease" demonstrated clearance of microvascular deposits in kidneys and heart via enzyme replacement, offering a model for cystinosis therapies. Yu et al. (2010) in "Termination of autophagy and reformation of lysosomes regulated by mTOR" linked autophagy impairment to disease progression, supporting interventions to restore lysosomal function.
Reading Guide
Where to Start
"Prevalence of Lysosomal Storage Disorders" by Meikle et al. (1999), as it provides an accessible entry on the collective burden of disorders like cystinosis, establishing their public health relevance before diving into molecular details.
Key Papers Explained
Meikle et al. (1999) in "Prevalence of Lysosomal Storage Disorders" sets the epidemiological context for lysosomal disorders including cystinosis. Mishra et al. (2003) in "Identification of Neutrophil Gelatinase-Associated Lipocalin as a Novel Early Urinary Biomarker for Ischemic Renal Injury" builds on this by identifying NGAL for early renal damage detection, crucial for cystinosis monitoring. Yu et al. (2010) in "Termination of autophagy and reformation of lysosomes regulated by mTOR" advances understanding of lysosomal-autophagy defects central to cystinosis pathogenesis. Eng et al. (2001) in "Safety and Efficacy of Recombinant Human α-Galactosidase A Replacement Therapy in Fabry's Disease" offers a parallel enzyme replacement model applicable to cystinosis therapies.
Paper Timeline
Most-cited paper highlighted in red. Papers ordered chronologically.
Advanced Directions
Current frontiers emphasize CTNS gene mutation impacts on autophagy, mitochondrial function, and pentose phosphate pathway disruptions, with no recent preprints or news available to indicate shifts.
Papers at a Glance
| # | Paper | Year | Venue | Citations | Open Access |
|---|---|---|---|---|---|
| 1 | On the Determination of Cystine as Cysteic Acid | 1963 | Journal of Biological ... | 3.0K | ✓ |
| 2 | [70] Determination of glutathione and glutathione disulfide in... | 1985 | Methods in enzymology ... | 2.7K | ✕ |
| 3 | Prevalence of Lysosomal Storage Disorders | 1999 | JAMA | 2.2K | ✕ |
| 4 | Gadolinium – a specific trigger for the development of nephrog... | 2006 | Nephrology Dialysis Tr... | 1.8K | ✓ |
| 5 | The Metabolic Basis of Inherited Diseases | 1972 | Archives of Dermatology | 1.8K | ✕ |
| 6 | Identification of Neutrophil Gelatinase-Associated Lipocalin a... | 2003 | Journal of the America... | 1.7K | ✕ |
| 7 | Fibroblast Growth Factor 23 and Mortality among Patients Under... | 2008 | New England Journal of... | 1.7K | ✓ |
| 8 | Safety and Efficacy of Recombinant Human α-Galactosidase A Rep... | 2001 | New England Journal of... | 1.5K | ✓ |
| 9 | Termination of autophagy and reformation of lysosomes regulate... | 2010 | Nature | 1.5K | ✓ |
| 10 | Time trends in reported prevalence of kidney stones in the Uni... | 2003 | Kidney International | 1.4K | ✓ |
Frequently Asked Questions
What is nephropathic cystinosis?
Nephropathic cystinosis is a rare genetic lysosomal storage disorder caused by CTNS gene mutations leading to cystine accumulation in lysosomes. It results in renal Fanconi syndrome, progressive kidney failure, ocular manifestations like corneal cystine crystals, and complications in other organs. Cysteamine therapy depletes lysosomal cystine to delay renal damage.
How does cysteamine therapy work in cystinosis?
Cysteamine therapy reduces lysosomal cystine accumulation by converting cystine to cysteine-cysteamine mixed disulfide, which exits lysosomes via lysine transporters. It slows progression of renal failure and improves ocular outcomes when used topically or systemically. Studies highlight its role alongside CTNS gene research in managing the disorder.
What are the prevalence and collective impact of lysosomal storage disorders?
Individually, lysosomal storage disorders like cystinosis are rare genetic diseases, but as a group they are relatively common. Meikle et al. (1999) in "Prevalence of Lysosomal Storage Disorders" reported they represent an important health problem in Australia. This underscores the need for newborn screening and targeted therapies.
What role does autophagy play in cystinosis pathophysiology?
Autophagy impairment occurs in cystinosis due to lysosomal cystine overload disrupting lysosome reformation. Yu et al. (2010) in "Termination of autophagy and reformation of lysosomes regulated by mTOR" showed mTOR regulates these processes essential for cellular homeostasis. Restoring autophagy is a potential therapeutic target for mitochondrial and renal complications.
Which biomarkers are used for renal injury in cystinosis-related research?
Neutrophil gelatinase-associated lipocalin (NGAL) serves as an early urinary biomarker for ischemic renal injury relevant to cystinosis complications. Mishra et al. (2003) in "Identification of Neutrophil Gelatinase-Associated Lipocalin as a Novel Early Urinary Biomarker for Ischemic Renal Injury" identified NGAL via transcriptome analysis post-ischemia. It enables early detection ahead of traditional markers like creatinine.
What is the significance of CTNS gene mutations?
CTNS gene mutations cause defective cystinosin transport protein, leading to lysosomal cystine retention in nephropathic cystinosis. This drives renal tubular dysfunction, glomerular sclerosis, and extrarenal issues like retinopathy. Research focuses on genotype-phenotype correlations to guide cysteamine dosing and prognosis.
Open Research Questions
- ? How can cysteamine therapy be optimized to better penetrate lysosomes and prevent long-term renal transplantation in cystinosis patients?
- ? What are the precise mechanisms linking CTNS mutations to autophagy impairment and mitochondrial dysfunction in multiple organs?
- ? Can early biomarkers like NGAL predict progression from Fanconi syndrome to end-stage renal disease in cystinosis?
- ? How do interactions between the pentose phosphate pathway and transaldolase deficiency exacerbate cystinosis pathophysiology?
- ? What strategies can restore lysosomal reformation regulated by mTOR in cystinosis models?
Recent Trends
The field maintains 25,200 works with no specified five-year growth rate.
High-citation classics like Moore in "On the Determination of Cystine as Cysteic Acid" (3015 citations) and Anderson (1985) in "[70] Determination of glutathione and glutathione disulfide in biological samples" (2717 citations) underscore foundational assays for cystine and oxidative stress relevant to cystinosis.
1963No recent preprints or news coverage indicate ongoing activity without new public data.
Research Biomedical Research and Pathophysiology with AI
PapersFlow provides specialized AI tools for Medicine researchers. Here are the most relevant for this topic:
Systematic Review
AI-powered evidence synthesis with documented search strategies
AI Literature Review
Automate paper discovery and synthesis across 474M+ papers
Find Disagreement
Discover conflicting findings and counter-evidence
Paper Summarizer
Get structured summaries of any paper in seconds
See how researchers in Health & Medicine use PapersFlow
Field-specific workflows, example queries, and use cases.
Start Researching Biomedical Research and Pathophysiology with AI
Search 474M+ papers, run AI-powered literature reviews, and write with integrated citations — all in one workspace.
See how PapersFlow works for Medicine researchers